Create a free account to unlock these features!
Create a free account to unlock these features!
| Overview | News | Financials | People | Insider Trades | Compensation | Holdings | Ownership | Corporate Family |
| Name: | Genzyme Corp |
| Industries: | Healthcare |
| Revenue: | $4.52B ¹ |
| Profit: | $422.30M ¹ |
| Employees: | 11,000 |
| Headquarters: | ONE KENDALL SQ CAMBRIDGE, Massachusetts 02139 United States Of America |
| Website: | |
| Lists: |
| #56 | Best Performers In Health |
Genzyme gets to the heart of high-tech healthcare. Founded in 1981 and headquartered in Cambridge, MA, Genzyme Corporation (NASDAQ: GENZ) is a biotechnology company focusing on genetic disorders, renal disease, cancer, transplants, orthopedics, and diagnostic testing. It is also extending its reach into immune disease, infectious disease, and other areas. The company had 2008 revenue of about $4.6 billion and employs about 11,000 people. In November 12008, it announced a new research collaboration
Genzyme gets to the heart of high-tech healthcare. Founded in 1981 and headquartered in Cambridge, MA, Genzyme Corporation (NASDAQ: GENZ) is a biotechnology company focusing on genetic disorders, renal disease, cancer, transplants, orthopedics, and diagnostic testing. It is also extending its reach into immune disease, infectious disease, and other areas. The company had 2008 revenue of about $4.6 billion and employs about 11,000 people. In November 12008, it announced a new research collaboration with the International Center for Genetic Engineering and Biotechnology, a not-for-profit research and development (R&D) organization, to advance treatments for neglected diseases such as malaria.
|
13 hours: |
|
|
|
3/17/10: |
Isis Drug Phase III Data Published - Analyst Blog
|
|
|
|
3/17/10: |
Isis Drug Phase III Data Published
|
|
|
|
3/16/10: |
Carl Icahn's 6 Biggest Busts … Is Genzyme Next?
|
|
|
|
3/16/10: |
Genzyme inspection finds drug impurity
|
|
|
|
3/15/10: |
Carl Icahn's 6 Biggest Busts - Will Genzyme Be No. 7?
|
|
|
|
3/15/10: |
Drug Company CEO Compensation Makes as Little Sense This Year
...
|
|
|
|
3/15/10: |
Mipomersen Phase 3 Study in HoFH Patients Featured in The Lancet
|
|
|
|
3/12/10: |
Genzyme discloses contamination at Ireland plant
|
|
|
|
3/12/10: |
Genzyme: CEO compensation down 25%
|
|
| Income (in thousands of USD) |
3 months ending 2009-12-31 |
12 months ending 2009-12-31 |
| Revenue | 1,080,630 | 4,515,525 |
| Net Income | 23,245 | 422,300 |
| Balance Sheet (in thousands of USD) | ||
| Current Assets | 2,802,803 | 2,802,803 |
| Total Assets | 10,060,724 | 10,060,724 |
| Current Liabilities | 1,080,130 | 1,080,130 |
| Total Liabilities | 2,377,072 | 2,377,072 |
| Total Shareholders Equity | 7,683,652 | 7,683,652 |
| Cash Flow (in thousands of USD) | ||
| Cash from Operating Activity | 222,456 | 1,179,037 |
| Cash from Investing Activity | -184,343 | -671,424 |
| Cash from Financing Activity | 26,521 | -336,616 |
| Change in Cash | 62,687 | 170,140 |
| Key Stats |
3 months ending 2009-12-31 |
Trailing 12 Months |
| Gross Profit Margin | 64.80% | 69.30% |
| Net Profit Margin | 2.15% | 9.35% |
| Return on Assets | 0.23% | 4.20% |
| Return on Equity | 0.30% | 5.50% |
| Return on Invested Capital | 0.21% | 4.64% |
